NOTE: This disposition is nonprecedential.

United States Court of Appeals for the Federal Circuit

CARDIOVALVE LTD., Appellant

v.

EDWARDS LIFESCIENCES CORPORATION, EDWARDS LIFESCIENCES LLC, Appellees

2022-2230

Appeal from the United States Patent and Trademark Office, Patent Trial and Appeal Board in No. IPR2021-00383.

Decided: March 21, 2024

SARA TONNIES HORTON, Willkie Farr & Gallagher LLP, Chicago, IL, argued for appellant. Also represented by DEVON WESLEY EDWARDS, New York, NY; DAVID PHILLIP EMERY, WILLIAM MANDIR, Sughrue Mion, PLLC, Washington, DC.

JOSHUA STOWELL, Knobbe, Martens, Olson & Bear, LLP, Irvine, CA, argued for appellees. Also represented by BRIAN C. BARNES, CRAIG S. SUMMERS.

Before TARANTO, CHEN, and STOLL, Circuit Judges.

TARANTO, Circuit Judge.

Cardiovalve Ltd. owns U.S. Patent No. 10,226,341, titled "Implant for Heart Valve." Edwards Lifesciences Corporation and Edwards Lifesciences LLC (collectively, Edwards) successfully petitioned the Patent and Trademark Office (PTO) to institute an inter partes review of claims 1–3, 5, 6, 8–11, and 13–21 of the '341 patent under 35 U.S.C. §§ 311–19. After review, the PTO's Patent Trial and Appeal Board determined in relevant part that all of the challenged claims were unpatentable for obviousness over U.S. Patent No. 7,635,329 (Goldfarb). *Edwards Lifesciences Corp. v. Cardiovalve Ltd.*, No. IPR2021-00383, 2022 WL 2812478, at *40 (P.T.A.B. July 18, 2022) (*Board Decision*). Cardiovalve appeals. We have jurisdiction under 28 U.S.C. § 1295(a)(4)(A). We affirm.

Ι

The '341 patent describes, with a particular focus on heart valves, "a prosthetic valve support . . . for facilitating minimally invasive (e.g., transcatheter and/or transluminal) implantation of a prosthetic valve at a native valve of a subject." '341 patent, col. 1, lines 53–56; *see also id.*, col. 1, lines 31–34. Independent claim 1, which the parties agree is representative, recites:

1. Apparatus for use at a native valve of a subject, the native valve including at least a first native leaflet and a second native leaflet, the apparatus comprising:

an implant, comprising:

DOCKE

RM

an annular portion, being configured to be placed against an upstream side of the

native valve, and having an inner perimeter that defines an opening, and

at least one leaflet clip:

(i) coupled to the annular portion,

(ii) comprising:

at least two clip arms, movable with respect to each other to open and close the clip; and

a clip-controller interface, the clip-controller interface being coupled to at least one of the clip arms, and

(iii) configured:

to be coupled to a portion of the first native leaflet by the clip arms being brought together to close around the first native leaflet,

to be coupled to a portion of the second native leaflet by the clip arms being brought together to close around the second native leaflet, and

to hold together the portion of the first leaflet and the portion of the second leaflet; and

a delivery apparatus, configured to deliver the implant to the native valve, and comprising at least one clip controller, the at least one clip controller being reversibly couplable to the clip-controller interface, and configured to facilitate opening and

DOCKE

RM

closing of the clip, and the delivery apparatus being intracorporeally decouplable from the implant.

Id., col. 27, lines 10–41 (emphases added).

Goldfarb discloses, in one of its embodiments, a device for stabilizing heart valve leaflets. Goldfarb, col. 17, lines 20–22. Figure 9B of Goldfarb illustrates this device, which is being inserted from above, so that upper is proximal and lower is distal from the inserter's perspective:




FIG. 9B

Id., fig.9B. The disclosed fixation device, 14, includes two proximal elements, 16, and two distal elements, 18, configured such that a proximal and distal element pair, when brought together, form a clip that grasps a heart valve leaflet, LF, from the top and bottom. *Id.*, col. 17, lines 29–37. The fixation device also includes flaps, 104, which restrict upward motion of the leaflets to better enable the proximal and distal elements to grasp the leaflets. *Id.*, col. 17, lines 38–50. Additionally, Goldfarb discloses that "[o]nce the leaflets have been grasped, the flaps . . . may be removed . . . or *may be left behind* to assist in holding the leaflets." *Id.*, col. 17, lines 51–53 (emphasis added).

RM

Cardiovalve does not dispute that Goldfarb discloses every limitation of the claims of the '341 patent other than the requirement that the implant comprise "at least one leaflet clip" "coupled to the annular portion." Further, Cardiovalve accepts that each of Goldfarb's pairs of proximal and distal elements constitutes a "leaflet clip," that each of Goldfarb's flaps constitutes or contains an "annular portion," and that any direct or indirect attachment of Goldfarb's proximal and distal elements to Goldfarb's flaps is a "coupl[ing]." *See* Cardiovalve Opening Br. at 32–33, 38–47; *see also Board Decision*, at *18. The Board found that Goldfarb makes the disputed claim element obvious, *id.*, at *16– 20, and concluded that Edwards had established obviousness, *id.*, at *21.

Π

On appeal, Cardiovalve's only challenge is that the Board erred in determining that Edwards had shown that it would have been obvious to a relevant artisan to attach, either directly or indirectly, Goldfarb's flaps to its proximal and distal elements. We reject this challenge.

"Obviousness is a question of law based on underlying findings of fact." In re Kubin, 561 F.3d 1351, 1355 (Fed. Cir. 2009). We decide obviousness de novo but review for substantial-evidence support the Board's subsidiary fact findings, including the presence or absence of a motivation to combine or modify teachings in the prior art, the presence or absence of a reasonable expectation of success, and the predictability of results from known methods. See PGS Geophysical AS v. Iancu, 891 F.3d 1354, 1363 (Fed. Cir. 2018); In re Stepan Co., 868 F.3d 1342, 1345–46 (Fed. Cir. 2017); Intelligent Bio-Systems, Inc. v. Illumina Cambridge Ltd., 821 F.3d 1359, 1366 (Fed. Cir. 2016); TriMed, Inc. v. Stryker Corp., 608 F.3d 1333, 1341 (Fed. Cir. 2010).

The Board here invoked the passage in the Supreme Court's opinion in *KSR International Co. v. Teleflex Inc.* that addresses proof of obviousness through a

DOCKE

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.